OTC · IGXT
Healthcare · Biotechnology
$0.17
Up+$0.00 (+0.00%)
Updated Aug 24, 2026, 7:54 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
IGXT does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning IGXT.
IGXT research
Company profile and research snapshot.
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 28, 2024 | LEEDE JONES GABLE | Buy | — |
| Mar 27, 2024 | LEEDE JONES GABLE | Buy | — |
| Jul 28, 2023 | LEEDE JONES GABLE | Buy | — |
| Jul 27, 2023 | LEEDE JONES GABLE | Buy | — |
| Jun 2, 2023 | LEEDE JONES GABLE | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 21, 2024
The global thin film drug manufacturing market is expected to grow from $6.4 billion in 2023 to $16.5 billion by 2034, driven by increasing demand for innovative drug delivery systems that enhance patient compliance and improve therapeutic outcomes.
GlobeNewswire Inc. · Jul 19, 2024
IntelGenx, a drug delivery company, announced that the Phase 1 Non-Binding LOI Submission Deadline for its previously announced sale and investment solicitation process (SISP) has lapsed. As Phase 1 did not result in alternative superior bids, IntelGenx and atai Life Sciences AG have initiated the process to complete the purchase and sale transaction.
GlobeNewswire Inc. · Jun 11, 2024
MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an order (as amended or amended and restated from time to time, the “Initial Order”) under the Companies’ Creditors Arrangement Act (the “CCAA” and the “CCAA Proceedings”) by the Superior Court of Québec (the “Court”). EY was appointed as monitor (in such capacity, the “Monitor”).
GlobeNewswire Inc. · May 28, 2024
MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) -- As previously announced on May 17, 2024, IntelGenx Technologies Corp. (the “Company” or “IntelGenx”) (OCTQB: IGXT; TSX: IGX), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, was granted protection pursuant to an initial order (as amended, the “Initial Order”) issued under the Companies' Creditors Arrangement Act (“CCAA”) by the Québec Superior Court (Commercial Division) (the “Court”). The Initial Order appointed Ernst & Young Inc. as monitor (the “Monitor”) and authorized interim debtor-in-possession financing (DIP) financing provided by atai Life Sciences AG in order to allow the Company to continue its operations during the restructuring process and implement the necessary restructuring measures.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IGXT.
No results
No recent SID articles mention IGXT.
